Aptose Biosciences Inc. (OTC: APTOF, TSX: APS) announced that enrollment is open for the 160 mg dosing cohort of tuspetinib ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE